Dr. Reddy’s Laboratories Q2FY26 Concall Decoded – The Doctor Prescribes GLP-1, Biosimilars & Calm Amid Price Erosion
1. Opening Hook
Big Pharma’s in a patent crisis and every chemist worth his molecule is chasing Semaglutide dreams. Amid all this, Dr. Reddy’s quietly drops a 10% revenue bump — even with Lenalidomide fading faster than a Diwali sparkler. The Hyderabad-based pharma giant is now playing a high-stakes game: betting on GLP-1s, biosimilars, and a nicotine patch habit it just acquired from Haleon.
Revlimid may be retiring, but Dr. Reddy’s isn’t — it’s rebranding from a generics workhorse to a biotech bull. And yes, the lab coat has pockets deep enough for $310 million in cash. Keep reading; the molecules get sexier later. 💊
2. At a Glance
Revenue ₹8,805 Cr (+9.8% YoY): Lenalidomide shrunk, but nicotine patches and Indian pills puffed it up.
EBITDA ₹2,351 Cr (+3% YoY): Margins stable at 26.7%; steady pulse, no fever.
PAT ₹1,437 Cr (+14% YoY): Revlimid gone, profits still dosing fine.
India biz ₹1,578 Cr (+13% YoY): 9th in IPM — and climbing like a multivitamin.
R&D ₹620 Cr (7% of sales): Doctor’s still experimenting, just 15% less expensively.
Net Cash ₹2,751 Cr ($310 Mn): Not bad for a company fighting tariffs and CRLs.
3. Management’s Key Commentary
“We delivered steady performance despite lower Lenalidomide.” (Translation: We finally stopped depending on that one cash cow. Time to milk new ones.*)
“EBITDA margin stood at 26.7%, steady sequentially.” (Flat is the new up in pharma.)
“Semaglutide, Abatacept, Denosumab are progressing well.” (The holy trinity of our future PowerPoint slides.)
“Acquired Stugeron from Janssen, and NRT portfolio from Haleon.” (From cancer care to curing cigarettes — truly diversified healthcare.)
“FDA issued Form 483s and a CRL on Rituximab, but we’re addressing it.” (USFDA drama continues: Indian pharma’s longest-running soap opera.) 😏
